Holen Sie sich die Stockscreener-App
3.49
2.35%
0.08
Handel nachbörslich:
3.50
0.010
+0.29%
Schlusskurs vom Vortag:
$3.41
Offen:
$3.35
24-Stunden-Volumen:
1.49M
Relative Volume:
0.98
Marktkapitalisierung:
$520.29M
Einnahmen:
$181.41M
Nettoeinkommen (Verlust:
$-59.56M
KGV:
-6.7115
EPS:
-0.52
Netto-Cashflow:
$-38.83M
1W Leistung:
+6.40%
1M Leistung:
+14.05%
6M Leistung:
+66.99%
1J Leistung:
+73.63%
1-Tages-Spanne:
$3.35
$3.569
1-Wochen-Bereich:
$3.17
$3.569
52-Wochen-Spanne:
$1.69
$3.87
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Vergleichen Sie XERS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
3.49 | 520.29M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Applied Therapeutics Appoints John H. Johnson as Executive Chairman - The Manila Times
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2%What's Next? - MarketBeat
Quantbot Technologies LP Purchases Shares of 15,425 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Walleye Capital LLC Purchases Shares of 1,121,738 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $237,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
XERS (Xeris Biopharma Holdings) Revenue : $187.4 Mil (TTM As of Sep. 2024) - GuruFocus.com
Xeris Biopharma Holdings (FRA:2B30) Other Long Term Assets : €4.9 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Other Stockholders Equity : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) EPS (Diluted) : $-0.44 (TTM As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) GF Score : 75/100 (As of Nov. 26, 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Accounts Payable : $7.5 Mil (As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Sells 578,313 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference - Business Wire
GSA Capital Partners LLP Trims Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
XERS (Xeris Biopharma Holdings) Cash-to-Debt : 0.26 (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Shares Outstanding (EOP) : 149.0 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Other Current Liabilities : $34.8 Mil (As of Sep. 2024) - GuruFocus.com
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): When Will It Breakeven? - Simply Wall St
HC Wainwright Forecasts Reduced Earnings for Xeris Biopharma - Defense World
Wealth Enhancement Advisory Services LLC Invests $35,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
FY2024 EPS Estimate for Xeris Biopharma Raised by Analyst - Defense World
HC Wainwright Forecasts Higher Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Neutral at Piper Sandler - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
HC Wainwright Forecasts Weaker Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Xeris Biopharma posts record revenue in Q3 2024 - Investing.com India
Earnings call: Xeris Biopharma posts record revenue in Q3 2024 By Investing.com - Investing.com Nigeria
Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highli - GuruFocus.com
Xeris Biopharma Reports Record Third Quarter Revenue - TipRanks
Xeris Biopharma Holdings Inc (XERS) Quarterly 10-Q Report - Quartzy
Xeris raises revenue outlook on strong 3rd-quarter results - Crain's Chicago Business
Xeris Biopharma Reports Third Quarter 2024 Financial Results - BioSpace
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Xeris Biopharma Holdings Inc Reports Q3 2024 Revenue of $54.3M, Beating Estimates; EPS Misses at ($0.11) - GuruFocus.com
Xeris Biopharma: Q3 Earnings Snapshot - San Francisco Chronicle
Xeris Biopharma (XERS) to Release Earnings on Friday - Defense World
Xeris Biopharma (XERS) Scheduled to Post Quarterly Earnings on Friday - MarketBeat
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 - BioSpace
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive - Seeking Alpha
SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Manufacturers Life Insurance Company Buys 5,291 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Xeris Biopharma Holdings Inc (XERS) had a good session last reading, didn’t it? - US Post News
Dimensional Fund Advisors LP Sells 6,437 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schmid John P. | Director |
Aug 12 '24 |
Buy |
2.25 |
4,515 |
10,147 |
25,200 |
| Schmid John P. | Director |
Aug 09 '24 |
Buy |
2.37 |
4,285 |
10,134 |
20,685 |
| Schmid John P. | Director |
May 10 '24 |
Buy |
1.91 |
5,400 |
10,314 |
16,400 |
| JOHNSON JOHN | Director |
Mar 18 '24 |
Option Exercise |
1.99 |
215,600 |
429,044 |
751,412 |
| Schmid John P. | Director |
Mar 14 '24 |
Buy |
2.16 |
4,500 |
9,720 |
11,000 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):